retatrutide mechanism of action retatrutide clinical trials 2024 2025 Diagram showing the of What is the detailed mechanism

Appetite Suppression Differences Most people report powerful appetite suppression on both pure GLP-1 agonists and dual agonists

Maintaining healthy habits alongside medication can play an important role in achieving lasting results

FDA-approved weight loss medications (semaglutide and tirzepatide) require either a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia

Four individual GLP-1 receptor agonists have now demonstrated MACE superiority in their dedicated cardiovascular outcome trials: Liraglutide: LEADER trial Semaglutide: SUSTAIN-6 and the landmark SELECT trial Dulaglutide: REWIND trial Albiglutide: HARMONY trial The SELECT trial deserves special attention because it broke entirely new ground

In fact, I would say that lower dose Reta would probably be superior for a lot of people than higher dose tirzepatide even though Lilly seems like it will position this for people with more advanced metabolic disease and at a price point that makes lower dose cost prohibitive anyway

15 Reasons for Caution Not all the data points in the same direction, though